Molecular structure of AAL-993, CAS Number: 269390-77-4
AAL-993 (CAS 269390-77-4)
Alternate Names:
VEGFR Tyrosine Kinase Inhibitor VI; 2-((4-Pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide
Application:
AAL-993 is a cell permeable inhibitor of VEGFR-1 (Flt-1), VEGFR-2 (Flk-1) and VEGFR-3 (Flt-4)
CAS Number:
269390-77-4
Purity:
≥98%
Molecular Weight:
371.36
Molecular Formula:
C20H16N3OF3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AAL-993 is a highly potent inhibitor of Flt-1 (VEGFR-1), Flk-1 (VEGFR-2) and Flt-4 (VEGFR-3) (IC50=130nM, IC50=23nM and IC50=18nM respectively). At higher concentrations it inhibits PDGFR-beta (640nM), c-Kit (236nM) and c-Fms-CSF-1R (CSF-1R) (380nM). AAL-993 shows no activity towards other kinases such as EGFR, FGFR-1, CDK-1, Tie-2, c-Met, IGF-1R, c-Src and c-Abl. An X-ray crystal structure of AAL-993 complexed with the catalytic domain of diphosphorylated VEGFR-2 indicates that this molecule binds to an inactive conformation of the protein.
AAL-993 (CAS 269390-77-4) References
- A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. | Bogoyevitch, MA. and Fairlie, DP. 2007. Drug Discov Today. 12: 622-33. PMID: 17706543
- Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature. | Crean, S., et al. 2009. Curr Drug Saf. 4: 143-54. PMID: 19442108
- Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. | Lee, K., et al. 2010. Eur J Med Chem. 45: 5420-7. PMID: 20869793
- Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. | West, XZ., et al. 2010. Nature. 467: 972-6. PMID: 20927103
- Small molecule kinase inhibitors as anti-cancer therapeutics. | Chahrour, O., et al. 2012. Mini Rev Med Chem. 12: 399-411. PMID: 22303944
- Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. | Benedito, R., et al. 2012. Nature. 484: 110-4. PMID: 22426001
- Cell-trappable fluorescent probes for endogenous hydrogen sulfide signaling and imaging H2O2-dependent H2S production. | Lin, VS., et al. 2013. Proc Natl Acad Sci U S A. 110: 7131-5. PMID: 23589874
- Synthesis and biological evaluation of novel anthranilamide derivatives as anticancer agents. | Liu, J., et al. 2013. Drug Discov Ther. 7: 144-52. PMID: 24071576
- Solar-driven photoelectrochemical probing of nanodot/nanowire/cell interface. | Tang, J., et al. 2014. Nano Lett. 14: 2702-8. PMID: 24742186
- Fluorescent probes for hydrogen sulfide (H2S) and sulfane sulfur and their applications to biological studies. | Shimamoto, K. and Hanaoka, K. 2015. Nitric Oxide. 46: 72-9. PMID: 25461270
- Azide-based fluorescent probes: imaging hydrogen sulfide in living systems. | Lin, VS., et al. 2015. Methods Enzymol. 554: 63-80. PMID: 25725516
- Prostaglandin F2α promotes angiogenesis and embryo-maternal interactions during implantation. | Kaczynski, P., et al. 2016. Reproduction. 151: 539-52. PMID: 26908918
- Heterogeneity in VEGF Receptor-2 Mobility and Organization on the Endothelial Cell Surface Leads to Diverse Models of Activation by VEGF. | da Rocha-Azevedo, B., et al. 2020. Cell Rep. 32: 108187. PMID: 32997988
Inhibitor of:
Angiogenesis, c-Fms-CSF-1R, c-Kit, Flk-1, Flt-1, Flt-4, PDGFR-beta, and Reg Iα.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AAL-993, 5 mg | sc-221195 | 5 mg | $255.00 | |||
AAL-993, 25 mg | sc-221195A | 25 mg | $816.00 |